The stock of IceCure Medical Ltd experienced a significant uptick on Tuesday following the announcement of groundbreaking findings in an independent study. This study, titled “Single-Probe Percutaneous Cryoablation with Liquid Nitrogen for the Treatment of T1a Renal Tumors,” was recently published in Cancers, shedding light on the prowess of IceCure’s innovative system in re-treating initially resistant tumors, achieving an unprecedented local control rate of 100%.
At the time of this publication, Icecure Medical Ltd stock (ICCM) has witnessed a surge.
Icecure Medical Ltd
Current Price: $1.40
Change : +0.66
Change (%): (89.07%)
Volume: 70.9M
Source: Tomorrow Events Market Data
Authored by a team of eight esteemed physicians in France, including interventional radiologists and urologists from institutions such as the Curie Institute, Paris, Nîmes University Hospital (University of Montpellier), Nîmes, and Carémeau University Hospital, Nîmes, the study focused on evaluating the safety and efficacy of IceCure’s ProSense® in treating malignant small renal masses.
ProSense®, already approved for treating both benign and malignant kidney tumors in the U.S., Europe, and various other countries, showcased its prowess in addressing the challenges associated with managing small renal masses, particularly in terms of recurrence rates. The study delved into the safety and efficiency of single-probe percutaneous cryoablation, presenting it as a potential solution.
In the retrospective study, 25 patients underwent cryoablation for 26 T1a renal tumors, with a median tumor size of 25.3 mm and a median RENAL nephrometry score of 7, indicating tumor complexity. The investigation meticulously assessed the causes behind partial tumor response and persistent tumor residue following a T1a renal cryoablation procedure.
IceCure Medical emphasized the study’s revelation that an impressive 92.4% of patients were discharged the day after cryoablation. Notably, the study underscored the IceCure system’s pivotal role in preserving renal function post-treatment, a factor paramount for enhancing patients’ overall quality of life.
Eyal Shamir, CEO of IceCure, commented on the findings, stating, “The authors’ findings align with the interim results from our own ICESECRET study in small renal masses, demonstrating an 89.5% recurrence-free rate. We anticipate the completion of ICESECRET’s five-year patient follow-up in 2026, with topline results available shortly afterward.”
The impact of these groundbreaking findings resonated in the financial markets, driving IceCure Medical Ltd’s stock to climb substantially amid heavy trading volume. Data from Te revealed that more than 70.9 million shares were traded during the session, a staggering figure that far exceeded the stock’s 100-day average of 2.448 million shares.
Investors and stakeholders are closely monitoring the developments, recognizing the potential transformative implications of IceCure’s innovative approach in the realm of tumor treatment. The surge in stock prices reflects the market’s optimism and confidence in the company’s trajectory as it continues to contribute to advancements in medical science and patient care.
